Aluminium salts such as aluminium chlorohydrate (ACH) are the active ingredients of antiperspirant products. Their mechanism of action involves a temporary and superficial plugging of eccrine sweat pores at the skin surface. We developed a microfluidic system that allows the real time observation of the interactions between sweat and ACH in conditions mimicking physiological sweat flow and pore dimensions. Using artificial sweat containing bovine serum albumin as a model protein, we performed experiments under flowing conditions to demonstrate that pore clogging results from the aggregation of proteins by aluminium polycations at specific location in the sweat pore. Combining microfluidic experiments, confocal microscopy and numerical models helps to better understand the physical chemistry and mechanisms involved in pore plugging. The results show that plugging starts from the walls of sweat pores before expanding into the centre of the channel. The simulations aid in explaining the influence of ACH concentration as well as the impact of flow conditions on the localization of the plug. Altogether, these results outline the potential of both microfluidic confocal observations and numerical simulations at the single sweat pore level to understand why aluminium polycations are so efficient for sweat channel plugging.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7973555 | PMC |
http://dx.doi.org/10.1038/s41598-021-85691-8 | DOI Listing |
Mikrochim Acta
January 2025
Indian Institute of Technology (BHU), Varanasi, 221005, India.
In the modern age, half of the population is facing various chronic illnesses due to glucose maintenance in the body, major causes of fatality and inefficiency. The early identification of glucose plays a crucial role in medical treatment and the food industry, particularly in diabetes diagnosis. In the past few years, non-enzymatic electrochemical glucose sensors have received a lot of interest for their ability to identify glucose levels accurately.
View Article and Find Full Text PDFLab Chip
January 2025
Antwerp Engineering, Photoelectrochemistry and Sensing (A-PECS), University of Antwerp, Groenenborgerlaan 171, 2020 Antwerp, Belgium.
Wearable microfluidic sweat sensors could play a major role in the future of monitoring health and wellbeing. Sweat contains biomarkers to monitor health and hydration status, and it can provide information on drug intake, making it an interesting non-invasive alternative to blood. However, sweat is not created in excess, and this requires smart sweat collection strategies to handle small volumes.
View Article and Find Full Text PDFIJID Reg
March 2025
Aklilu Lemma Institute of Pathobiology, Addis Ababa University, Addis Ababa, Ethiopia.
Objectives: To assess tuberculosis (TB) and associated factors among patients with presumptive TB with chronic kidney disease (CKD).
Methods: A prospective cross-sectional study was conducted from January to December 2023 among 381 patients with CKD attending six hospitals found in five regions of Ethiopia. Sputum and urine specimens were collected and examined for TB using smear microscopy, culture, and Xpert MTB/RIF Ultra assay.
Ecotoxicol Environ Saf
January 2025
North China University of Water Resources and Electric Power, Zhengzhou 450046, China.
The ecology of watersheds plays an important role in regulating regional climate and human activities. The sediment-soil system in the middle and lower reaches of the Yellow River Basin (Henan section) was explored. The spatial distribution characteristics of heavy metals (HMs) showed that tributaries, which are affected by anthropogenic activities, contain higher concentrations of HMs than the main channel.
View Article and Find Full Text PDFEur Clin Respir J
January 2025
Adult Cystic Fibrosis Centre, The Prince Charles Hospital, Brisbane, Queensland, Australia.
Therapeutic drug monitoring (TDM) of elexacaftor/tezacaftor/ivacaftor (ETI) remains challenging due to a lack of clarity around the parameters that govern ETI plasma concentrations, whilst the use of concomitant CYP3A inducers rifabutin and rifampicin is not recommended. We present the complexities of TDM for ETI performed in a person with cystic fibrosis and refractory pulmonary disease. Utilising National Association of Testing Authorities (NATA) accredited assays and target considerations published by the Therapeutic Goods Administration (TGA), Australia, ETI plasma concentration variability was monitored over the course of an acute admission with added complexity from an antibiotic regimen including rifabutin, a moderate cytochrome P450 3A (CYP3A) inducer, and clofazimine, a mild CYP3A inhibitor.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!